For advanced NSCLC patients, immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors have been established as first-line therapy regimen [8,9]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.